Skip to main content

Ropinirole Side Effects

Medically reviewed by Drugs.com. Last updated on Jan 3, 2022.

Summary

Commonly reported side effects of ropinirole include: syncope, dizziness, drowsiness, dyskinesia, fatigue, nausea, orthostatic hypotension, viral infection, decreased blood pressure, decreased pulse, and increased pulse. Other side effects include: asthenia, confusion, lower extremity edema, hallucination, hypotension, systolic hypertension, vertigo, and diaphoresis. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to ropinirole: oral tablets

Side effects include:

Patients with early parkinsonian syndrome (without levodopa): Nausea, dizziness, somnolence, syncope, vomiting, fatigue, viral infection, dyspepsia, pain, leg edema, increased sweating, asthenia, dependent edema, orthostatic symptoms, abdominal pain, pharyngitis, abnormal vision, dry mouth, hypertension, confusion, hallucinations, urinary tract infection.

Patients with advanced parkinsonian syndrome (with concomitant levodopa): Dyskinesia, nausea, dizziness, somnolence, headache, hallucinations, falls, abdominal pain, confusion, upper respiratory tract infection, increased sweating, vomiting, arthralgia, tremor, anxiety, urinary tract infection, constipation, pain, hypokinesia, paresthesia, diarrhea, amnesia, nervousness.

Patients with restless legs syndrome: Nausea, somnolence, vomiting, dizziness, fatigue.

For Healthcare Professionals

Applies to ropinirole: oral kit, oral tablet, oral tablet extended release

Gastrointestinal

Parkinson's disease:

Very common (10% or more): Nausea (up to 60%), vomiting (up to 12%)

Common (1% to 10%): Dry mouth, abdominal pain, anorexia, dyspepsia, flatulence, constipation, diarrhea, dysphagia, increased saliva, heartburn

Restless Leg Syndrome:

Very common (10% or more): Nausea (up to 40%), vomiting (up to 12.9%)

Common (1% to 10%): Diarrhea, dyspepsia, dry mouth, abdominal pain upper

Uncommon (0.1% to 1%):[Ref]

Nervous system

Parkinson's disease

Very common (10% or more): Dizziness (40%), somnolence (40%), dyskinesia (34%), headache (17%)

Common (1% to 10%): Hyperkinesia, hypesthesia, hypokinesia, paresis, paresthesia, tremor

Uncommon (0.1% to 1%): Sudden onset of sleep, excessive daytime somnolence

Restless Leg Syndrome:

Very common (10% or more): Headache (up to 22.3%), somnolence (12%), dizziness (up to 12.9%)

Common (1% to 10%): Paresthesia, migraine, paradoxical augmentation and rebound of restless leg syndrome[Ref]

Psychiatric

Parkinson's disease

Very common (10% or more): Hallucination (10%)

Common (1% to 10%): Amnesia, impaired concentration, confusion, amnesia, anxiety, abnormal dreaming, nervousness

Uncommon (0.1% to 1%): Psychotic reactions other than hallucinations, included delirium, delusions, paranoia

Frequency not reported: Aggression

Postmarketing reports: Impulse control disorders included pathological gambling and hypersexuality and increased libido

Restless Leg Syndrome:

Common (1% to 10%): Nervousness

Postmarketing reports: Impulse control disorders included pathological gambling and hypersexuality and increased libido[Ref]

Cardiovascular

Parkinson's disease:

Very common (10% or more): Syncope (up to 12%)

Common (1% to 10%): Hypertension, hypotension, orthostatic symptoms, chest pain, dependent edema, leg edema, flushing, extrasystoles, atrial fibrillation, palpitation, tachycardia, peripheral ischemia

Restless Leg Syndrome:

Common (1% to 10%): Syncope

Uncommon (0.1% to 1%): Orthostatic hypotension, peripheral edema

Frequency not reported: Hypotension[Ref]

Immunologic

Common (1% to 10%): Influenza, viral infection[Ref]

General

The most commonly reported adverse reaction reported in patients with early Parkinson's disease included nausea, somnolence, dizziness, syncope, asthenic conditions, viral infection, leg edema, vomiting, and dyspepsia. Among patients with advance Parkinson's disease, the more commonly reported adverse reactions included dyskinesia, somnolence, nausea, dizziness, confusion, hallucinations, sweating, and headache.

The most commonly reported adverse reactions in patients with restless legs syndrome included nausea, vomiting, somnolence, dizziness, and a asthenic condition.[Ref]

Respiratory

Parkinson's disease

Common (1% to 10%): Yawning, upper respiratory tract infection, dyspnea, bronchitis, pharyngitis, rhinitis, sinusitis

Restless Leg Syndrome:

Very common (10% or more): Upper respiratory infection (10.7%)

Common (1% to 10%): Nasopharyngitis, cough, nasal congestion, rhinitis, sinusitis[Ref]

Ocular

Parkinson's disease:

Common (1% to 10%): Eye abnormality, abnormal vision, xerophthalmia, diplopia[Ref]

Metabolic

Parkinson's disease

Common (1% to 10%): Decreased weight[Ref]

Genitourinary

Common (1% to 10%): Impotence, urinary tract infection, pyuria, urinary incontinence, urinary tract infection[Ref]

Other

Parkinson's disease

Very common (10% or more): Asthenic condition (16%)

Common (1% to 10%): Pain, vertigo

Restless Leg Syndrome:

Very common (10% or more): Fatigue (10.4%)

Common (1% to 10%): Asthenic condition, vertigo

Postmarketing reports:[Ref]

Asthenic conditions include asthenia, fatigue, and/or malaise[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, arthritis, extremity pain, back pain, injury, myalgia[Ref]

Dermatologic

Common (1% to 10%): Increased sweating[Ref]

Hematologic

Parkinson's disease

Common (1% to 10%): Anemia[Ref]

Hepatic

Parkinson's disease

Common (1% to 10%): Increased alkaline phosphatase

Frequency not reported: Increased liver enzymes[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity reactions including urticarial, angioedema, rash, pruritus[Ref]

References

1. "Product Information. Requip (ropinirole)." SmithKline Beecham (2001):

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.